Dividends & Buybacks ·
Atossa declares one stapled CVR per share entitling holders to up to $50M of priority review voucher proceeds
ATOSAtossa Therapeutics, Inc.
Atossa Therapeutics declared a dividend of one stapled contingent value right (CVR) for each share of common stock outstanding as of the October 19, 2026 record date. The CVRs grant shareholders a contractual right to receive 25% of the net proceeds from the sale or deemed monetization of Atossa's first qualifying FDA priority review voucher, subject to an aggregate payment cap of $50 million. Payments are contingent on the award and monetization of a voucher by December 31, 2036, with no assurance that any payment will occur. The CVRs remain stapled to common stock until detached by the Board. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and rare diseases.